Deciphera shares skyrocket as cancer drug improves progression-free survival

Deciphera Pharmaceuticals Inc's shares more than doubled on Tuesday after the drugmaker said its late-stage study met the main goal of helping stomach cancer patients live longer without their disease worsening.